Phospho-EIF4E (S209) Antibody

Code CSB-RA007556A209phHU
Size US$350Purchase it in Cusabio online store
(only available for customers from the US)
Image
  • Western Blot
    Positive WB detected in 293 whole cell lysate,HepG2 whole cell lysate(treated with Calyculin A or not)
    All lanes Phospho-EIF4E antibody at 1.2μg/ml
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 25 KDa
    Observed band size: 25 KDa

  • IHC image of CSB-RA007556A209phHU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. P06730
Target Names EIF4E
Alternative Names AUTS19 antibody; CBP antibody; eIF 4E antibody; eIF 4F 25 kDa subunit antibody; EIF 4F antibody; eIF-4E antibody; eIF-4F 25 kDa subunit antibody; eIF4E antibody; EIF4E1 antibody; EIF4EL1 antibody; EIF4F antibody; Eukaryotic translation initiation factor 4 E antibody; Eukaryotic translation initiation factor 4E antibody; Eukaryotic translation initiation factor 4E like 1 antibody; IF4E_HUMAN antibody; Messanger RNA Cap Binding Protein eIF 4E antibody; MGC111573 antibody; mRNA cap binding protein antibody; mRNA cap-binding protein antibody
Species Reactivity Human
Immunogen A synthesized peptide derived from Human Phospho-EIF4E (S209)
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Clonality Monoclonal
Isotype Rabbit IgG
Clone No. 1F3
Purification Method Affinity-chromatography
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form Liquid
Tested Applications ELISA, WB, IHC
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:50-1:200
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures. Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression. In the CYFIP1-EIF4E-FMR1 complex this subunit mediates the binding to the mRNA cap.
Gene References into Functions
  1. Mechanisms of translation initiation control via the eIF4E hub are pertinent to deregulated lymphoblastic activity. [review] PMID: 29527921
  2. High EIF4F expression is associated with malignant glioma. PMID: 30066885
  3. Our study...suggests that methylation of cg11037477 and expression of EIF4E may act as prognostic markers in gastric cancer PMID: 29342273
  4. Lack of regulation of the interaction between the eIF4E/eIF4G subunits of the translation initiation factor complex eIF4F is a hallmark of cancer. The inhibitor 4EGI-1 binds to eIF4E, thereby preventing association with eIF4G through an allosteric mechanism. Binding of 4EGI-1 perturbs native correlated motions and increases correlated fluctuations in part of the eIF4G binding site. PMID: 27162083
  5. The findings suggest that AEG-1 promotes gastric cancer metastasis through upregulation of eIF4E-mediated MMP-9 and Twist. PMID: 28661037
  6. The authors show that the eukaryotic translation initiation factor eIF4E, an oncoprotein, drives hyaluronan biosynthesis. eIF4E stimulates production of enzymes that synthesize the building blocks of hyaluronan, UDP-Glucuronic acid and UDP-N-Acetyl-Glucosamine, as well as hyaluronic acid synthase which forms the disaccharide chain. PMID: 29111978
  7. The present study indicated that miR-15a downregulation was associated with cell proliferation and invasion by directly targeting eIF4E during RCC progression. PMID: 28849086
  8. High expressions of eIF-4E are associated with advanced stage and poor prognosis. PMID: 28242042
  9. Our results indicate that AURKA plays an important role in the activation of EIF4E and cap-dependent translation. Targeting the AURKA-EIF4E-c-MYC axis using alisertib is a novel therapeutic strategy that can be applicable for everolimus-resistant tumors and/or subgroups of cancers that show overexpression of AURKA and activation of EIF4E and c-MYC PMID: 28073841
  10. Treatment with 240 mg/l matrine reduced the protein expression levels of PCNA and eIF4E. Matrine also reduced the migration ability of A549 cells and inhibited their proliferation, which may be associated with the overexpression of p53 and p21, and the reduction of PCNA and eIF4E expression levels. PMID: 28447756
  11. eIF4E and MMP9 expression in endometrial cancer specimens suggests their potential up-regulation during carcinogenesis. PMID: 29254314
  12. eIF4E promoted cholangiocarcinoma cell metastasis by up-regulating the expression of VEGF-C, MMP-2 and suppressing E-cadherin expression. PMID: 27907907
  13. Translational initiation pathway inhibition could be of clinical utility in male breast cancer patients overexpressing eIF4E and eIF5. With mTOR inhibitors that target this pathway now in the clinic, these biomarkers may represent new targets for therapeutic intervention, although further independent validation is required PMID: 27986751
  14. Data show association of eIF4E expression with chemotherapeutic response in esophageal squamous cell carcinoma (ESCC), and suggest that therapeutically targeting eIF4E may be a viable means of improving chemotherapy response in ESCC. PMID: 27588477
  15. We performed bioinformatics analyses of ESTs and the 3'UTRs of the main transcript splice variants of the translational initiation factor eIF4E1 and its family members, eIF4E2 and eIF4E3. We propose to elucidate the minor splice variants of eIF4E2 and eIF4E3 in great detail because they might produce proteins with modified features that fulfill different cellular roles from their major counterparts. PMID: 28942592
  16. EIF4E associated signaling pathways are associated with lymphangiogenesis and lymph node metastases of hypopharyngeal cancer. PMID: 29374693
  17. The authors show that LARP1 directly binds the cap and adjacent 5'TOP motif of TOP mRNAs, effectively impeding access of eIF4E to the cap and preventing eIF4F assembly. Thus, LARP1 is a specialized TOP mRNA cap-binding protein that controls ribosome biogenesis. PMID: 28379136
  18. Mitogen-activated protein kinase interacting protein kinases (Mnks) control translation by phosphorylation of eIF4E, whereas the mTOR kinase phosphorylates/de-activates the eIF4E inhibitor, 4E-BP1, to release translational repression. PMID: 27094611
  19. Elevated levels of p-Mnk1, p-eIF4E and p-p70S6K proteins are associated with tumor recurrence and poor prognosis in astrocytomas. Overexpression of p-eIF4E and co-expression of p-Mnk1, p-eIF4E and p-p70S6K proteins could be used as novel independent poor prognostic biomarkers for patients with astrocytomas. PMID: 27900644
  20. PRMT1 inhibition prevents gastric cancer progression by downregulating eIF4E and targeting type II PRMT5. PMID: 28987382
  21. MNK-1 controls chemokine secretion and proliferation in human airway smooth muscle cells. PMID: 27418099
  22. Data indicate that combinations of androgen receptor (AR) and mechanistic target of rapamycin (mTOR) inhibitors were effective in suppressing tumor growth including bicalutamide increased eukaryotic initiation factor 4E (eIF4E) phosphorylation. PMID: 28745319
  23. cell signaling pathways are activated in DIAs; peIF4E is an independent prognostic factor and a promising therapeutic target. PMID: 27440383
  24. Study identified and established the presence of an evolutionarily conserved water-bridge structural module which is an integral component of the recognition of the 5' mRNA cap by eIF4E during the process of translation initiation. PMID: 27916520
  25. Here, the authors identify the domains responsible for the eIF4E/human rhinovirus 2 2A(pro) interaction using molecular modelling and describe mutations that impair this interaction and delay in vitro cleavage of eIF4G isoforms. PMID: 28843814
  26. Results suggest that IGF2BP3 promotes eIF4E-mediated translational activation through the reduction of EIF4E-BP2 via mRNA degradation, leading to enhanced cell proliferation. PMID: 26522719
  27. There were significantly higher expressions of p-eIF4E and p-4EBP-1 proteins in the cases with lymph node metastasis than in those without lymph node metastasis. PMID: 28395726
  28. Our studies provide the first biochemical framework for the eIF4E-dependent mRNA export pathway. PMID: 28325843
  29. Human endogenous eIF4E1 and eIF4E2 behave under stresses similarly as their GFP-tagged counterparts. PMID: 27578149
  30. High EIF4E expression is associated with malignant peripheral nerve sheath tumors and vestibular schwannomas. PMID: 26951381
  31. The structures of eIF4E-eIF4G complexes reveal an extended interface to regulate translation initiation. PMID: 27773676
  32. 4E-BP1 has tumor suppressor activity by inhibiting eIF4E and, thus, blocking mRNA translation and proliferation. This is corroborated by elevated levels of phosphorylated and hence inactive 4E-BP1, which are detected in various cancers PMID: 26829052
  33. The studies suggest that MNK-eiF4E axis controls the translation of specific mRNAs in cancer metastasis and neuronal synaptic plasticity by a novel mechanism involving the regulation of the translational repressor, CYFIP1. (Review) PMID: 27527252
  34. Alternative eIF4F complexes taking part in protein biosynthesis have been described. (Review) PMID: 27283511
  35. Data show that galeterone (gal) and VNPT55 inhibit migration and invasion of prostate cancer cells, possibly by down-regulating protein expression via antagonizing the Mnk1/2-eIF4E axis. PMID: 27618366
  36. Findings suggest that miR-455-3p functions as a tumor suppressor by directly targeting eIF4E in prostate carcinogenesis. PMID: 28350134
  37. Data show that targeting translation initiation (TI) factors eIF4E/eIF4GI reduces migration and epithelial-to-mesenchymal transition (EMT), both essential for metastasis, thereby underscoring the potential of TI targeting in non-small cell lung cancer (NSCLC) therapy. PMID: 27501049
  38. p4E-BP1 may identify male breast cancers potentially suitable for therapies directed at the upstream kinase, mTOR PMID: 27280636
  39. eIF4E and mTOR depletion significantly enhances the anti-proliferative and pro-apoptotic effects of paclitaxel, demonstrating the critical role of eIF4E in oral tongue squamous cell carcinoma cell response to paclitaxel PMID: 27932243
  40. data suggest a physiological role for MNK1a-Ser(353) phosphorylation in regulation of the MNK1a kinase, which correlates with increased eIF4E phosphorylation in vitro and in vivo. PMID: 27413184
  41. eIF4E may play an important role in the development and metastasis of hypopharyngeal carcinoma; its expression may be helpful in establishing the diagnosis, stage and prognosis of this tumour type. PMID: 24840750
  42. First study showing the induction of miR-141/EIF4E expression in an acquired model of docetaxel chemoresistant patients with non-small cell lung cancer. PMID: 27840955
  43. miR503 may increase sensitivity to therapies at least partially through targeting EIF4E suppression of Hepatocellular carcinoma proliferation. PMID: 27840964
  44. suggests that selective inhibition of translation of YB-1 mRNA, and probably some other mRNAs as well, by mTOR kinase inhibitors is not mediated by the action of the 4E-binding protein upon functions of the 4F-group translation initiation factors PMID: 26931209
  45. eIF4E protein might result in the malignant progression of hepatocellular carcinoma, and its overexpression may be a powerful prognostic biomarker. PMID: 27601163
  46. HSP27 was found to be regulator of translation initiation and STAT3 level. Therefore, it suggests that HSP27 is a key protein during placental development and trophoblast cell differentiation. PMID: 27714564
  47. Cercosporamide acts as a Mnk inhibitor to block eIF4E phosphorylation and selectively suppresses angiogenesis, growth and survival of human hepatocellular. PMID: 27662474
  48. Our studies also suggest that nuclear entry is important for the prooncogenic activity of eIF4E, at least in this context. These findings position nuclear trafficking of eIF4E as a critical step in its regulation and position the importin 8-eIF4E complex as a novel therapeutic target. PMID: 27114554
  49. Two distinct cap-dependent protein synthesis machineries select mRNAs for translation: the normoxic eIF4F and the hypoxic eIF4Fhigh. PMID: 26854219
  50. This study demonstrates that the activation of eIF4E gene is an essential component of the malignant phenotype in ovarian cancer PMID: 26498997

Show More

Hide All

Involvement in disease Autism 19 (AUTS19)
Subcellular Location Cytoplasm, P-body, Cytoplasm
Protein Families Eukaryotic initiation factor 4E family
Database Links

HGNC: 3287

OMIM: 133440

KEGG: hsa:1977

UniGene: Hs.13211

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1